Search Results

Displaying Results 1-1 of 1 "'GLPG'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight

Mar 10, 2026, 17:31 ET CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight

related diseases; increasing awareness of CD19-targeted therapies; and a growing pipeline of investigational drugs such as Obexelimab (Zenas BioPharma), GLPG5101 (Galapagos NV), IKS 03 (Iksuda Therapeutics), ANKTIVA + CD19 t-haNK (ImmunityBio), NKX019 (Nkarta), CABA-201 (Cabaletta Bio), CLN-978 (Cullinan

More news about: DelveInsight Business Research, LLP

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.